Compare OXSQ & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | PLX |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 182.9M |
| IPO Year | 2003 | 1996 |
| Metric | OXSQ | PLX |
|---|---|---|
| Price | $1.35 | $2.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.3M | 658.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.10 | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $3.61 | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.40 | ★ $9.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.05 | $1.60 |
| 52 Week High | $2.15 | $3.19 |
| Indicator | OXSQ | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 61.38 |
| Support Level | $1.30 | $2.59 |
| Resistance Level | $1.43 | $2.71 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 44.00 | 80.77 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.